A study presented at this year’s ASCO Quality Care Symposium examined predictors of compliance with payer-led oncology clinical pathways.
2022
Healthy gut microbiome improves success of cancer treatment
Healthy gut microbiome improves success of cancer treatment
Relatlimab-Nivolumab Combo Deemed Promising in Resectable Melanoma
Combination relatlimab and nivolumab yields a high pathologic complete response (pCR) rate in patients with resectable stage III or oligometastatic stage IV melanoma, according to a study published in Nature.
Timely treatment of melanoma helps improve patient survival
Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.